In what represents Vienna, Austria-based Valeriot GmbH’s first patenting, its founder and CEO, Michael Flatscher, describes their invention of a device, Autovein, for use in no-touch vein harvesting which overcomes the issues faced with traditional vein harvesting techniques which are laborious, prone to complications and challenging to master.

In what represents the first patenting from Munich, Germany-based Meliodys Medical UG, its co-founder and chief executive officer Simone Sabbione describes their development of a hormone-free, local pain management approach for treating dysmenorrhea, which aims to address the condition while minimizing the occurrence of side effects.

Skin biopsies could be a thing of the past thanks to the development of a new non-invasive microneedle patch to pre-screen for skin cancer. Dermr Health Solutions Pty Ltd. founder and CEO Stefan Mazy told BioWorld that the fledgling genomics startup company is pushing the boundaries of science with its Dermr patch that quickly and painlessly extracts live skin cells in 15 seconds, drastically cutting the time and discomfort associated with traditional biopsy procedures.

The first patenting from Hemeo BV describes its development of Vantage, an artificial intelligence powered clinical decision support software for coagulation management.

In Ciconia Medical Inc.’s first patenting, the company’s founder and CEO, Roni Cantor-Balan, describes the development of a cervical measurement device for childbirth progress monitoring that replaces the manual vaginal examinations undertaken during labor.

In what represents the first patenting to emerge from Endeavor Med Inc., its founder and chief executive officer, Imran Faruqi, describes their development of a novel device capable of providing non-invasive cardiac pacing, defibrillation, and cardioversion, and which uses pacing currents at less than half that required by traditional chest pads.

In Pumpkinseed Technologies Inc.’s first public patenting, the company’s co-founders describe their development of new proteomics platform that merges nanotechnology, biochemistry, silicon photonics and machine learning for high-resolution phenotyping to deliver new biological insights.

The first patenting to emerge in the name of Copenhagen, Denmark-based 1Health Gut In Balance ApS (dba Gut In Balance) describes development of an apparatus and system that enables hospitals to produce fecal microbiota transplantation capsules on site, and much more efficiently and cheaply.

The first patenting to be published in the name of Wave View Imaging Inc. sees its co-founders file for additional protection of their imaging technology which can be used to monitor breast cancer treatment.

Beyond its success in migraine and attention deficit hyperactivity disorder, Nu Eyne Co. Ltd. is advancing a portfolio of noninvasive, wearable trigeminal nerve stimulation devices across key three areas of neuromodulation, tissue regeneration and proliferation inhibition.